89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.

Research output: Contribution to conference › Poster › Academic

Original language	English
DOIs	https://doi.org/10.1200/JCO.2020.38.15_suppl.3573
Publication status	Published - 2020
Event	ASCO 2020 Virtual Annual Meeting - Duration: 1 Jun 2020 → …

Conference	ASCO 2020 Virtual Annual Meeting
Period	1/06/2020 → …

Access to Document

@conference{8834725c26984c5d8592af5177e04e76,

title = "89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.",

author = "J Voortman",

year = "2020",

doi = "https://doi.org/10.1200/JCO.2020.38.15_suppl.3573",

language = "English",

note = "ASCO 2020 Virtual Annual Meeting ; Conference date: 01-06-2020",

}

TY - CONF

T1 - 89Zr-durvalumab PD-L1 PET in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck.

AU - Voortman, J

PY - 2020

Y1 - 2020

UR - http://10.1200/JCO.2020.38.15_suppl.3573

U2 - https://doi.org/10.1200/JCO.2020.38.15_suppl.3573

DO - https://doi.org/10.1200/JCO.2020.38.15_suppl.3573

M3 - Poster

T2 - ASCO 2020 Virtual Annual Meeting

Y2 - 1 June 2020

ER -